128 results about "Right ventricles" patented technology

The invention belongs to the technical field of medicines, and discloses an application of a small molecule compound in preparation of a product for preventing and / or treating pulmonary arterial hypertension and complications thereof. The small molecule compound is 8-[[4-(cyclopropanecarbonyl) piperazine-1-yl] methyl]-1, 3-dimethyl-7-(3-methylbutyl) purine-2, 6-diketone, and the structural formula is as shown in a formula (I): # imgabs0. The small molecule compound and pharmaceutically acceptable salts thereof have a remarkable treatment effect on pulmonary arterial hypertension and complications thereof, and can be used for treating pulmonary arterial hypertension and complications thereof. The effects of preventing and / or treating the pulmonary arterial hypertension include the reduction of right heart hypertrophy, the reduction of right ventricular systolic pressure, right heart enlargement, right heart dysfunction, pulmonary vascular remodeling, pulmonary arterial intima thickness, increase of vascular myelization, pulmonary arterial smooth muscle cell proliferation and migration, the reduction of the right ventricular hypertrophy, the reduction of the right ventricular hypertrophy, the reduction of the right ventricular hypertrophy and the reduction of the right ventricular hypertrophy. The pulmonary arterial intima thickness and the vascular myelization level are improved, pulmonary vascular remodeling is reversed, and pulmonary artery smooth muscle cell proliferation and migration are inhibited.

A system for determining fluid responsiveness of a patient includes a hemodynamic sensor that produces, on an ongoing basis, a hemodynamic sensor signal representative of a right ventricular pressure (RVP) waveform of the patient and an integrated hardware unit. The integrated hardware unit includes a processor, a memory, and a display including a user interface. The memory includes instructions that, when executed by the processor, cause the system to receive the hemodynamic sensor signal representative of the RVP waveform of the patient, convert the RVP waveform of the patient into an estimate of a blood flow waveform of the patient, determine a stroke volume variation (SVV) of the patient based on the estimate of the blood flow waveform of the patient to generate a determined SVV, and output, to the display, an indication of a fluid responsiveness status of the patient that is based on the determined SVV.

Disclosed are a method for presenting cardiac myocardial strain and an ultrasound imaging apparatus, comprising: acquiring image data of myocardial segments of both left and right ventricles, and processing this data to obtain motion parameters of both left and right ventricular myocardial segments. A composite bull's-eye plot containing left and right ventricular bull's-eye subplots is displayed, wherein the left ventricular bull's-eye subplot comprises multiple left ventricular myocardial regions corresponding to the left ventricular myocardial segments and presenting motion parameters of the left ventricular myocardial segment; and the right ventricular bull's-eye subplot comprises a right ventricular myocardial region corresponding to the right ventricular myocardial segments that exclude some / all shared segments with the left ventricle and presenting motion parameters of the right ventricular myocardial segment. This configuration enables users to observe motion parameters of both ventricular myocardial segments, thereby providing comprehensive understanding of cardiac myocardial strain while enhancing clinical efficiency for doctors.

The invention provides a self-adaptive control method and device for a double-ventricle auxiliary system. The method comprises the steps that target aortic pressure detected by a first pressure sensor, target left ventricular end diastolic pressure detected by a second pressure sensor, target right atrial pressure detected by a third pressure sensor and target pulmonary artery pressure detected by a fourth pressure sensor are obtained; and determining a strategy for adjusting the left ventricular assist device or the right ventricular assist device according to the target left ventricular end diastolic pressure, the target right ventricular pressure and the target pulmonary arterial pressure when the peripheral perfusion of the target user is insufficient or the lung is over-perfused. The pressure sensors are arranged to detect the pressure of the inlets and the outlets of the left ventricular assist device and the right ventricular assist device, whether adverse events such as peripheral insufficiency or pulmonary hyperperfusion occur to a user or not is judged according to the detected pressure, and then the adverse events are relieved or even solved by adjusting the rotating speeds of the left ventricular assist device and the right ventricular assist device. And the safety of the user is greatly improved.

The present invention discloses the application of burdock root polysaccharide in the preparation of a medicament for treating pulmonary hypertension, belonging to the field of pharmaceutical technology. The present invention prepares a medicament for treating pulmonary hypertension with burdock root polysaccharide as the sole active ingredient. The medicament comprises an effective amount of burdock root polysaccharide and pharmaceutically acceptable excipients. Experimental results show that burdock root polysaccharide significantly reduces the increase in pulmonary artery pressure induced by monocrotaline in rats, significantly inhibits the increase in right ventricular hypertrophy index, significantly alleviates pulmonary artery endothelial injury, medial thickening, excessive proliferation of medial cells and infiltration of inflammatory cells in rats with pulmonary hypertension, significantly alleviates the degree of pulmonary artery vascular muscleization in rats with pulmonary hypertension, has the effects of reducing pulmonary artery vascular remodeling and lowering pulmonary artery pressure, and has a significant therapeutic effect on pulmonary hypertension and right ventricular hypertrophy in rats, and can be applied to the preparation of a medicament for treating pulmonary hypertension.

The invention relates to an application of a THBS4 inhibitor in preparation of a medicine for preventing and / or treating pulmonary arterial hypertension. Three pulmonary arterial hypertension rat models (a hypoxia induction model, a hypoxia combined SUGEN induction model and a monocrotaline induction model) are constructed, the expression change of THBS4 is verified through qRT-PCR and western blot, and the correlation between the expression level of THBS4 and pulmonary arterial hypertension is verified in combination with in-vitro cell experiments and in-vivo intervention. Results show that THBS4 is remarkably up-regulated in pulmonary arteries of the three models, the expression level of THBS4 is positively correlated with the severity of diseases, and THBS4 is an important regulatory factor for promoting vascular remodeling in pulmonary arterial hypertension. In vivo, by knocking down THBS4, pulmonary vascular remodeling and right ventricular hypertrophy are remarkably relieved, and it is prompted that THBS4 inhibitors show good application prospects in the aspect of preventing and / or treating pulmonary arterial hypertension.

The invention belongs to the technical field of medicines, and discloses application of WZ3146 in preparation of products for preventing and / or treating pulmonary arterial hypertension and complications thereof. The WZ3146 and the pharmaceutically acceptable salt thereof have a remarkable treatment effect on pulmonary arterial hypertension and complications thereof, such as mean pulmonary arterial pressure, high right ventricular systolic pressure, right heart enlargement, right heart dysfunction, pulmonary vascular remodeling, pulmonary arterial intima thickness, increase of vascular myelization, pulmonary artery smooth muscle cell proliferation and migration and the like; the effects of preventing and / or treating pulmonary arterial hypertension comprise expanding the right heart, improving the pulmonary arterial intima thickness and the vascular myelization level, reversing pulmonary vascular remodeling and inhibiting pulmonary artery smooth muscle cell proliferation and migration.

A system for determining placement of a catheter in a patient includes a hemodynamic sensor and a display. The hemodynamic sensor produces a signal representative of a right ventricular pressure waveform of the patient. The catheter is connected to the hemodynamic sensor. The system further includes one or more processors and computer-readable memory encoded with instructions that, when executed by the one or more processors, cause the system to receive the signal representative of the right ventricular pressure waveform and extract features from the right ventricular pressure waveform. The instructions further cause the system to compare the features to one or more value ranges of the features to determine that the catheter is correctly placed when values of the features are within the one or more value ranges or that the catheter is incorrectly placed, is not properly connected to the system, or signal quality issues are occurring.

A right ventricular assist device (hereinafter, “RVAD”) for placement inside a mammalian subject includes a tube having an inlet configured to be positioned in the mammalian subject when the tube is in a proper position within a heart and an outlet configured to be located in a pulmonary artery when the tube is in the proper position. The RVAD also includes a plurality of sensors having measurement locations along the tube to measure a plurality of pressures of blood exterior to the tube at the measurement locations and a controller in communication with the pump and the plurality of sensors that convey the plurality of pressures to the controller with the controller being configured to instruct the pump to pump blood through the tube depending on at least one of the plurality of pressures.

A tricuspid regurgitation treatment tool to be inserted into the pulmonary artery is proposed. The tricuspid regurgitation treatment tool to be inserted into the pulmonary artery is used to verify whether the right ventricular dysfunction may occur when treating the tricuspid regurgitation by surgeries or other permanent treatments. A test insertion of the tricuspid regurgitation treatment tool to be inserted into the pulmonary artery is made to pass obliquely through the tricuspid valve of a patient, and after a certain time has elapsed, the tool is removed. The tricuspid regurgitation treatment tool to be inserted into the pulmonary artery includes: a blocking part blocking the tricuspid valve; and an insertion tube provided with a guidewire-guiding lumen formed therein to be movable along the guidewire.

This invention discloses a floating temporary pacing lead with a pig-tail shaped tip, comprising a lead body, an air bladder and a conductive area at the tip of the lead body, an inflation tube and an electrode wire along the length of the lead body, the inflation tube communicating with the air bladder, and the electrode wire connected to the conductive area; the tip of the lead body is bent inward to form an unclosed loop pig tail loop, the air bladder is located inside the pig tail loop, and the conductive area is located outside the pig tail loop; by providing an inwardly bent, unclosed loop pig tail loop at the tip of the lead body, this application changes the contact between the lead body tip and the ventricular wall from point contact to surface contact, increasing the contact area between the pacing lead and the right ventricle, and the contact surface between the pacing lead and the ventricular wall is a smooth curve, avoiding complications such as ventricular wall perforation.

An implantable lead for use with an implantable medical device (IMD) includes a tubular lead body having a proximal portion including a proximal end, a distal portion including a distal end opposite the proximal end, and an intermediate portion between the proximal portion and the distal portion. A helical electrode extends distally from the distal end of the tubular lead body. At least one atrial electrode is disposed in the intermediate portion of the tubular lead body. At least one electrical conductor extends through the tubular lead body and is mechanically and electrically coupled to the helical electrode and the at least one atrial electrode. The intermediate portion may have a pre-formed bend configured to urge the at least one atrial electrode against a surface of the right atrium when the lead is implanted. A distal pre-formed bend located in the distal portion of the tubular lead body may be configured to bias a plurality of pacing / sensing electrodes towards a surface of a right ventricle. A distal pre-formed bend located in the distal portion of the tubular lead body may be configured to bias the helical electrode and at least one pacing / sensing against a surface of a right ventricle.

A system for monitoring right ventricular systolic dysfunction includes a hemodynamic sensor that produces a hemodynamic sensor signal representative of a right ventricular pressure waveform of the patient, a display, one or more processors, and computer-readable memory. The computer-readable memory is encoded with instructions that, when executed by the one or more processors, cause the system to receive the hemodynamic sensor signal representative of the right ventricular pressure waveform of the patient, extract right ventricular peak systolic pressure and right ventricular end diastolic pressure from the right ventricular pressure waveform of the patient, determine a ratio of right ventricular peak systolic pressure over right ventricular end diastolic pressure, and output the ratio of right ventricular peak systolic pressure over right ventricular end diastolic pressure to the display for monitoring the presence of right ventricular systolic dysfunction based on the ratio of peak systolic pressure over end diastolic pressure.

The invention discloses application of Axl in treatment of right heart failure ventricular remodeling. The invention relates to application of a substance for regulating Axl expression in preparation of a product for remodeling the structure and function of a right ventricle. The substance for regulating the expression of the Axl is used for overexpressing the Axl or inhibiting the expression of the Axl. Regulation and control of Axl target spots can significantly improve right ventricular remodeling, delay disease progression of right heart failure and improve the survival rate of patients.

The utility model discloses a fixing strap for a temporary pacemaker, which comprises a shoulder strap and a binding strap, an extension bag is sewed below the shoulder strap, a zipper is sewed on the surface of the extension bag, a weight is stored in the extension bag, and a binding surface is arranged at the bottom end of the extension bag; a traction piece is arranged on the surface of the extension bag and used for changing the position of the extension bag, and the fixing band is used in cooperation with the fixing band at the position, close to the apex of the right ventricle, of the extension bag after being worn, so that the fixing band can keep a good attaching effect whether daily activities or mild exercises are carried out; and the risk of complications caused by displacement of the pacemaker or poor contact of the electrodes is reduced. The bonding head is bonded to the bonding female end area by pulling the traction belt, it can be ensured that the position of the extension bag after adjustment is kept stable, that is, the position of the extension bag is changed through traction of the traction belt, and the position of the extension bag is accurately adjusted.

The application relates to a method for constructing a rat model of chronic obstructive pulmonary disease (COPD) related pulmonary arterial hypertension and application thereof, and belongs to the technical field of animal disease model construction. The method selects 6-8-week-old, 220+ / -10g healthy male SD rats, and all the rats are adaptively fed in a standard SPF level animal room for 7 days; then the rats are divided into a Con group and a COPD-PH group; the rats in the COPD-PH group are given 1mg / mL lipopolysaccharide by airway instillation on the first day and the 14th day; the rats are placed in a self-made whole-body inhalation smoking box for 1h every day from the 2nd day to the 13th day and from the 15th day to the 30th day; the rats enter a low-oxygen box for 8h every day during the light period from the 2nd day to the 13th day and from the 15th day to the 30th day; the rat model can simultaneously reproduce the characteristics of COPD and typical changes of pulmonary arterial hypertension, the right ventricular systolic pressure can be stably increased to 40-50mmHg, the right ventricular hypertrophy index can reach 0.40-0.50, the pulmonary vascular remodeling and inflammation are significant, and various indexes are stable and good in repeatability.

An arrhythmia type inference device includes: an obtaining section that obtains a target signal waveform indicating a time-series change in the area of a region, which is at least one of a left atrium, a left ventricle, a right atrium, and a right ventricle, the target signal waveform being generated by analyzing an image of a heart of a target subject; and an inference section that infers the type of tachyarrhythmia suffered by the target subject based on the shape of the target signal waveform having a frequency in a frequency band higher than a reference frequency band predetermined as a normal range. This allows the arrhythmia type inference device to accurately infer the type of tachyarrhythmia from the image obtained by image-capturing of the heart.

In some aspects, the invention teaches pharmaceutical compositions that include a TGF-β ligand trap, and methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-β signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-β ligand trap to reduce right ventricular systolic pressure in a subject.

The invention relates to the technical field of pulmonary artery risk assessment, in particular to a pulmonary arterial hypertension patient early prognosis prediction method combined with iconography analysis. The method comprises the following steps: dividing an analysis period of each patient into systole periods, and obtaining different motion behavior sets according to the area difference of standard right ventricle images in different systole periods of each patient and the position difference of the standard right ventricle images in the corresponding systole period; selecting an abnormal behavior set of the patients according to the area difference of the standard right ventricle images belonging to the same movement behavior set of each patient and other patients in the corresponding cardiac contraction cycles; and performing prognosis prediction on the patient according to the abnormal degree difference and the number difference of the standard right ventricle images in the abnormal behavior set of each patient and other patients. The condition that different patients are in the same motion state of the heart is analyzed, and the prognosis accuracy of the pulmonary arterial hypertension patients is effectively improved.

In some aspects, the invention teaches pharmaceutical compositions comprising a TGF-beta ligand trapping agent, and methods of using the TGF-beta ligand trapping agent to treat, prevent, or reduce the rate of progression of pulmonary hypertension (PH). The invention also provides methods of using the TGF-beta ligand trapping agents to treat, prevent, or reduce the rate of progression of a variety of disorders, the conditions include, but are not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using the TGF-beta ligand trapping agent to reduce right ventricular systolic pressure in a subject.

An intracardiac delivery catheter or assembly is disclosed. The delivery catheter includes a delivery lumen and a flow assist balloon inflatable through an inflation lumen. In illustrated embodiments the delivery lumen has a diameter dimension of at least 8 F, 9 F, 10 F or between 8-14 F for insertion of an intracardiac echocardiography catheter (ICE) for placement at an intracardiac imaging site. In embodiments described, the delivery catheter is used for placement of an ICE catheter in a pulmonary artery or other treatment site using an asymmetric balloon having an asymmetric profile and portion to steer the delivery catheter, for example, into the right ventricle and into the pulmonary artery.

A catheter (18A) is configured to deliver a lead (18) or other secondary device into a patient's heart (12). The catheter (18A) is configured to deliver the secondary device via a right ventricle (28) near a portion of a left bundle branch (8a) of the patient. The catheter (18A) comprises an elongate tubular member (14). The elongate tubular member (14) comprises: a proximal end (15a); a distal end (15b) sized for introduction into the body of a patient; and a lumen (14A) extending between the proximal end (15a) and the distal end (15b). The elongate tubular member (14) is preformed. The elongate tubular member (14) further includes a distal portion (150b) adjacent to the distal end (15b) and a proximal portion (99) adjacent to the proximal end (15a). The distal portion (150b) defines a curvilinear shape in a relaxed state. The curved shape comprises a curved second region (200) located in a first plane (17) and a curved fourth region (400) located in a second plane (19).

Described herein are pumps that linearly reciprocate to assist with circulating blood within the body of a patient. Red blood cell damage may be avoided or minimized by such linear pump movement. The linearly reciprocating movement may also generate a pulsatile pumping cycle that mimics the natural pumping cycle of the heart. The pumps may be configured to reside at various body locations. For example, the pumps may be situated within the right ventricle, the left ventricle, the ascending aorta, the descending aorta, the thoracic aorta, or the abdominal aorta. In some instances, the pump may be deployed within the venous circulation. In other instances, the pump may reside outside the patient.

The invention belongs to the technical field of medical treatment, particularly discloses an application of allicin in preparation of a medicine for improving right heart dysfunction caused by pulmonary arterial hypertension, and discloses an effect of the allicin in treatment of the right heart dysfunction caused by the pulmonary arterial hypertension. Compared with existing medicines (mainly for reducing pulmonary arterial pressure) for treating pulmonary arterial hypertension, allicin not only can reduce the pulmonary arterial pressure and relieve the symptoms of pulmonary arterial hypertension, but also can remarkably improve right heart dysfunction caused by pulmonary arterial hypertension, and the allicin is specifically shown as follows: (a) average pulmonary arterial pressure, pulmonary artery ejection time and pulmonary artery end diastolic inner diameter are reduced; the pulmonary artery acceleration time is prolonged; (b) the right ventricular systolic pressure, the right ventricular end-of-systolic free wall thickness, the right ventricular end-of-systolic free wall thickness, the right ventricular end-of-systolic inner diameter and the right heart hypertrophy index are reduced, and tricuspid valve displacement, stroke output and right heart discharge are increased; and (c) improving right ventricular and pulmonary vascular remodeling.

The present invention discloses a minimally invasive catheter-type right ventricular assist device. It comprises a cannula, an elastic metal support, a flexible film, an expandable-contractible balloon and a guide wire. The cannula is sequentially divided into a front section, a middle section and a tail section. The front section of the cannula is provided with a plurality of first inflow holes. The middle section of the cannula is a corrugated hose. The tail section of the cannula is provided with an outflow hole and a one-way valve is provided inside the tail section to control the one-way outflow of blood from the middle section to the tail section of the cannula. The elastic metal support is tightly attached to the outer surface of the cannula front section and limits deformation of the cannula front section. The flexible film is connected to the inner wall surface of the cannula front section, and its elastic modulus is smaller than that of the cannula front section. The flexible film surface is provided with a plurality of second inflow holes. The second inflow holes are arranged alternately with the first inflow holes and are located at non-overlapping positions. The expandable-contractible balloon is built into the cavity of the cannula front section to control blood intake and discharge. The guide wire passes through the cannula and extends from the tail section of the cannula.

A system for determining a global hypoperfusion index (GHI) includes an arterial blood pressure sensor, a ventricular blood pressure sensor, an oximetry module, and an integrated hardware unit including a system processor and a system memory. The system memory includes instructions that cause the system to receive arterial hemodynamic data, ventricular hemodynamic data, and blood oxygen saturation data. One or more right ventricular pressure features, one or more pulmonary artery pressure features, one or more cardiac output parameters, and one or more venous oxygen saturation parameters are derived from the arterial hemodynamic data, the ventricular hemodynamic data, and the blood oxygen saturation data. The GHI is derived by using a predictive decision model based upon the one or more right ventricular pressure features, the one or more pulmonary artery features, the one or more cardiac output parameters, and the one or more venous oxygen saturation parameters.

Methods and systems are provided for a rate adaptive bi-ventricular fusion pacing. The methods and systems deliver a first pulse at a left ventricular (LV) lead and a second pulse at a right ventricular (RV) lead based on a paced atrio-ventricular (AV) delay. The first pulse timed to be delivered concurrently with an intrinsic ventricular conduction. The methods and systems further repeat the delivery of the first pulse and the second pulse for a predetermined number of cycles. Additionally, the methods and systems measure an intrinsic AV conduction interval, and adjust the paced AV delay based on the intrinsic AV conduction interval and a negative hysteresis delta.

An ultrasound imaging and backscatter system includes an ICE ultrasound catheter having an ultrasound pMUT transducer array disposed within a distal end of the ultrasound catheter and including a plurality of transducer array elements disposed on a substrate. One end of the catheter shaft is connected to the handle assembly and the other end is connected to the ultrasonic transducer array. The catheter shaft accommodates an electronic flexible cable in communication with the signal trace and directs each of the plurality of transducer array elements to transmit and receive an ultrasound beam, receives at least one signal from the plurality of transducer array elements, and constructs at least one image characterizing one or more tissue components of the scanned object. An ultrasound imaging system is used to measure tissue thickness, tissue scar, and lesion assessment for left atrium, right atrium, left ventricle, and right ventricle tissue wall characteristics and other intracardiac tissue anomalies.

The present invention belongs to the field of pulmonary vascular disease treatment, and specifically discloses a TGF-β receptor inhibitor for the treatment of pulmonary hypertension. In the rat pulmonary hypertension model induced by monocrotaline (MCT), after using the preparation, the right ventricular systolic pressure (RVSP), right ventricular hypertrophy (Fulton index), pulmonary vascular resistance and vascular wall thickness of the rat can be reversed and reduced, and the survival rate of monocrotaline (MCT)-induced pulmonary hypertension rats can be prolonged. Compared with the modeling group, the expression of IL-17, IL-6 and GM-CSF inflammatory factors in the lung tissue of the preparation-treated group was significantly reduced, and the expression of extracellular matrix-related genes CTGF, Fn1 and Col1α1 also decreased. The preparation can significantly alleviate the pulmonary hypertension in rats induced by monocrotaline (MCT), showing good therapeutic effect and application prospects.

The invention relates to a system for attaching a heart valve. The function of the system (1) is to attach a heart valve (3) to a heart prosthesis (2) intended to be implanted within the pericardial cavity of a patient and to replace the natural left and right ventricles of the patient, the system (1) comprising a male ring (10) provided with nails (11) and a mating part (12) provided with an opening (13), the male ring (10) or the mating part (12) being intended to be fixed to the heart prosthesis (2), the staples (11) and the opening (13) are configured such that, in the attached position, the staples (11) pass through the flange (9) of the heart valve (3) and into the opening (13).